Skip to content

Insmed INSM Interest coverage

Interest coverage at other companies

United Therapeutics logo
United TherapeuticsUTHR
87.5×+48.2×
Incyte logo
IncyteINCY
689.3×+620×
Amgen logo
AmgenAMGN
3.9×+1.5×
ALN
Alnylam PharmaceuticalsALNY
3.4×+2.9×
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
101×+77.4×
Johnson & Johnson logo
Johnson & JohnsonJNJ
24.5×-1.7×

Other financials

Income statement

See full
Revenue$306.0M+230%
Gross profit$258.5M+261%
Operating income-$153.3M+38.2%
Net income-$163.6M+36.3%
EPS (diluted)-$0.76+46.5%

Balance sheet

See full
Cash & equivalents$582.2M+44.4%
Total debt$580.3M-49.2%
Total equity$704.9M+611%
Total assets$2.1B+15.2%

Cash flow

See full
Operating cash flow-$222.7M+15.0%
CapEx$3.5M-65.4%
Free cash flow-$226.2M+16.9%

Valuation

See full
Market cap$20.76B+155%
Enterprise value$20.76B+142%
P/S25.3×+4.0×

Profitability

See full
Gross margin81.8%+5.3pp
Operating margin-140.6%-43.9pp
Net margin-144.4%-45.3pp

Returns & leverage

See full
Return on equity-294.5%
Debt / equity0.8×-10.7×
Current ratio4.5×-1.4×

Where this comes from

Calculated from Insmed’s reported figures.

Based on trailing twelve months.

The official record: Insmed’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Insmed's interest coverage.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Insmed's interest coverage?
Insmed (INSM) reported interest coverage of -14× in Q1 2026.
How has Insmed's interest coverage changed year-over-year?
Insmed's interest coverage decreased by 21.9% year-over-year, from -11.5× to -14×.
What is the long-term trend for Insmed's interest coverage?
Over 4 years (2021 to 2025), Insmed's interest coverage has grown at a 7.3% compound annual growth rate (CAGR), from -39× to -51.8×.
What does interest coverage mean?
How many times the company's operating profit covers its interest bill.
How do you interpret interest coverage?
Higher is safer; below ~2× is a warning that earnings provide little cushion against the debt burden. Debt-free companies have no interest expense and the ratio is left blank.
How does interest coverage compare across companies?
Comparable across leveraged non-financials; less relevant for net-cash companies with negligible interest.